

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**EVEREST MEDICINES**

**云 頂 新 耀**

**Everest Medicines Limited**

**雲 頂 新 耀 有 限 公 司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1952)**

## **DALAY IN DESPATCH OF CIRCULAR**

Reference is made to the announcement of Everest Medicines Limited (the “**Company**”) dated 16 August 2022 (the “**Announcement**”) in relation to the Transaction. Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Announcement.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among other things, further details of the Transaction and the Termination and Transition Services Agreement, a notice convening the EGM and other information required under the Listing Rules will be despatched to the Shareholders on or before 30 September 2022.

As additional time is required for the Company to prepare and finalise certain information to be included in the Circular, including the statement of indebtedness, the working capital sufficiency statement of the Group, and other information as required to be disclosed under the Listing Rules, it is expected that the despatch date of the Circular will be postponed to a date falling on or before 26 October 2022.

By order of the Board  
**Everest Medicines Limited**  
**Wei Fu**  
*Chairman and Executive Director*

Hong Kong, 30 September 2022

*As at the date of this announcement, the Board comprises Mr. Wei Fu as Chairman and Executive Director, Mr. Yongqing Luo, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.*